Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
Michihito Sasaki, Koshiro Tabata, Mai Kishimoto, et al.
Science Translational Medicine (2022) Vol. 15, Iss. 679
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Accelerating antiviral drug discovery: lessons from COVID-19
Annette von Delft, Matthew D. Hall, Ann D. Kwong, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 585-603
Open Access | Times Cited: 94
Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
Jonathan Daniel Ip, Allen Wing‐Ho Chu, Wan-Mui Chan, et al.
EBioMedicine (2023) Vol. 91, pp. 104559-104559
Open Access | Times Cited: 67
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, et al.
JAMA Network Open (2024) Vol. 7, Iss. 2, pp. e2354991-e2354991
Open Access | Times Cited: 51
Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2
Yosuke Hirotsu, Hiroaki Kobayashi, Yumiko Kakizaki, et al.
Med (2023) Vol. 4, Iss. 11, pp. 813-824.e4
Open Access | Times Cited: 49
Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs
Girish Chandra, Durg Vijay Singh, Gopal Kumar Mahato, et al.
Chemical Papers (2023) Vol. 77, Iss. 8, pp. 4085-4106
Open Access | Times Cited: 44
In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
Maki Kiso, Seiya Yamayoshi, Shun Iida, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 39
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
Anne F. Luetkemeyer, Kara W. Chew, Stuart R. Lacey, et al.
Clinical Infectious Diseases (2025)
Open Access | Times Cited: 1
A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, et al.
Medicine (2023) Vol. 102, Iss. 8, pp. e33024-e33024
Open Access | Times Cited: 35
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective
Cecilia Pozzi, Anne Vanet, Valeria Francesconi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3664-3702
Open Access | Times Cited: 26
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
Conrad Fischer, Jenson R. Feys
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 80-107
Open Access | Times Cited: 24
Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains
Hawa Sophia Bouzidi, Jean‐Sélim Driouich, Raphaëlle Klitting, et al.
Antiviral Research (2024) Vol. 222, pp. 105814-105814
Open Access | Times Cited: 9
Ensitrelvir Fumaric Acid: First Approval
Yahiya Y. Syed
Drugs (2024) Vol. 84, Iss. 6, pp. 721-728
Closed Access | Times Cited: 8
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Viral proteases as therapeutic targets
Taťána Majerová, Jan Konvalinka
Molecular Aspects of Medicine (2022) Vol. 88, pp. 101159-101159
Open Access | Times Cited: 31
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Letian Song, Shenghua Gao, Bing Ye, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 87-109
Open Access | Times Cited: 19
Genetic conservation across SARS-CoV-2 non-structural proteins – Insights into possible targets for treatment of future viral outbreaks
Shubhangi Kandwal, Darren Fayne
Virology (2023) Vol. 581, pp. 97-115
Open Access | Times Cited: 15
A viral assembly inhibitor blocks SARS-CoV-2 replication in airway epithelial cells
Li Du, Fred Deiter, Mohamed S. Bouzidi, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 5
Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19
Yang Li, Si-Ming Lu, Jia-Long Wang, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33179-e33179
Open Access | Times Cited: 5
Optimization of SARS-CoV-2 Mpro Inhibitors by a Structure-Based Multilevel Virtual Screening Method
Lanlan Jing, Fabao Zhao, Lin Zheng, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 670-670
Open Access
Tea Catechins in Green Tea Inhibit the Activity of SARS-CoV-2 Main Protease via Covalent Adduction
Yoji Kato, Sakiko Suzuki, Akari Higashiyama, et al.
Journal of Agricultural and Food Chemistry (2025)
Closed Access
Decoding SARS‐CoV‐2 Inhibition: Insights From Molecular Dynamics Simulation of Condensed Amino Thiourea Scaffold Small Molecules
Xiaoli Shen, Hao Zhang, Pengyin Zhang, et al.
Journal of Cellular Biochemistry (2025) Vol. 126, Iss. 2
Closed Access
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals
Juliane Brun, Edi Dharmana, Michelle L. Hill, et al.
Antiviral Research (2025), pp. 106123-106123
Open Access
Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
Karen Anbro Gammeltoft, Yuyong Zhou, Line A. Ryberg, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1970-1970
Open Access | Times Cited: 12
Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
Wang Chun Kwok, Terence Chi Chun Tam, Jcm Ho, et al.
International Journal of COPD (2024) Vol. Volume 19, pp. 77-86
Open Access | Times Cited: 4
Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models
Hong‐Yi Zheng, Tian‐Zhang Song, Yong‐Tang Zheng
动物学研究 (2024) Vol. 45, Iss. 4, pp. 747-766
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top